Breaking Down Barriers to Transcatheter Aortic Valve Replacement
Why the study?
Although TAVR is the dominant treatment for symptomatic severe AS, underutilization of TAVR in these patients receives inadequate attention, prompting SCAI to explore causes of undertreatment and develop solutions to maximize access.
Design
Think tank proceedings and expert consensus
Authors
Discussion
Loading...
Member takes
Implication
Underscores barriers limiting TAVR access in severe AS; leaves open whether proposed solutions will reduce undertreatment.
Structured PICO
P
Population
Patients with symptomatic severe aortic stenosis (AS)
I
Intervention
Transcatheter aortic valve replacement (TAVR) and strategies to overcome barriers to its utilization
A multidisciplinary approach is required to address patient, diagnostic, and systemic barriers contributing to the significant undertreatment of severe symptomatic aortic stenosis.
Cite This Study
Vora et al. (2024) studied this question.